Imatinib Unknown Status Phase 2 Trials for Sclerosis, Progressive Systemic Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00573326Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
NCT00555581Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis